系统性红斑狼疮缓解期停用免疫抑制剂后复发的患病率及预测因素
该研究纳入1990至2018年诊断、曾用免疫抑制剂且仍在随访的SLE患者,评估缓解期停用免疫抑制剂后复发率及预测因素。139例(43.5%)停用免疫抑制剂,其中因缓解停药者24.7%复发,因依从性差/不耐受停药者67.6%复发。抗疟药维持治疗和停药时缓解持续时间是复发的独立保护因素。
要点
- 缓解期停用免疫抑制剂后复发并不少见,因缓解停药者24.7%复发。
- 抗疟药维持治疗和较长缓解持续时间可降低复发风险。
- 因依从性差/不耐受停药者复发率更高(67.6%)。
核心结论
- SLE患者停用免疫抑制剂后复发并不少见,即使在缓解期患者中也是如此。
- 抗疟药治疗和持久的缓解可显著降低复发风险。
研究设计与样本
- 回顾性队列研究,纳入1990至2018年诊断(符合ACR标准)、曾接受免疫抑制剂治疗且目前仍在随访的SLE患者。
- 共319例 eligible 患者,其中139例(43.5%)停用免疫抑制剂,105例(75.5%)因缓解停药,34例(24.5%)因依从性差/不耐受停药。
- 停药后平均随访91个月(标准差71,范围6-372)。
- 采用多因素logistic回归分析后续复发的预测因素。
主要发现
- 因缓解停药者中26/105(24.7%)复发,因依从性差/不耐受停药者中23/34(67.6%)复发(P < 0.001)。
- 两组复发患者的中位随访时间分别为57个月(范围6-264)和8个月(范围1-72)(P = 0.009)。
- 在因缓解停药的患者中,抗疟药维持治疗(OR 0.243,95% CI 0.070, 0.842)和停药时缓解持续时间(OR 0.870,95% CI 0.824-0.996)是复发的独立保护因素。
关键数值与推荐
- 缓解定义为临床SLEDAI-2K = 0,且维持稳定的免疫抑制剂和/或抗疟药治疗和/或泼尼松≤5 mg/天。
- 复发根据SLEDAI Flare Index定义。
- 停药定义为完全停用任何免疫抑制药物。
临床怎么用
- 对于SLE缓解期患者,停用免疫抑制剂前应评估缓解持续时间,并考虑继续抗疟药维持治疗以降低复发风险。
- 因依从性差或药物不耐受而停药的患者复发风险较高,需加强监测。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with SLE are often exposed to prolonged immunosuppression since few data on flare recurrence in remitted patients who discontinued immunosuppressants are available. We aimed to assess the rate and predictors of flare after immunosuppressant withdrawal in SLE patients in remission. METHODS: SLE patients diagnosed between 1990 and 2018 (according to the ACR criteria), ever treated with immunosuppressants and currently in follow-up were considered. Immunosuppressant discontinuation was defined as complete withdrawal of any immunosuppressive drug. Reasons for discontinuation were remission, defined as clinical SLEDAI-2K = 0 on a stable immunosuppressive and/or antimalarial therapy and/or on prednisone ⩽5 mg/day, or poor adherence/intolerance. Flares were defined according to the SLEDAI Flare Index. Predictors of a subsequent flare were analysed by multivariate logistic regression. RESULTS: There were 319 eligible patients out of 456 (69.9%). Of the 319 patients, 139 (43.5%) discontinued immunosuppressants, 105 (75.5%) due to remission, 34 (24.5%) due to poor adherence/intolerance. The mean (s.d.) follow-up time after immunosuppressant withdrawal was 91 (71) months (range 6-372). Among the patients who discontinued immunosuppressants, 26/105 remitted (24.7%) and 23/34 unremitted patients (67.6%) experienced a flare (P < 0.001) after a median (range) follow-up of 57 (6-264) and 8 months (1-72), respectively (P = 0.009). In patients who discontinued immunosuppressants due to remission, maintenance therapy with antimalarials (OR 0.243, 95% CI 0.070, 0.842) and the duration of remission at immunosuppressant discontinuation (OR 0.870, 0.824-0.996) were independent protective factors against disease flare. CONCLUSION: SLE flares are not uncommon after immunosuppressant discontinuation, even in remitted patients; however, antimalarial therapy and durable remission can significantly reduce the risk of flare.
引用
- Zen M, Saccon F, Gatto M, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. Rheumatology (Oxford). 2020. PMID: 31642908. doi:10.1093/rheumatology/kez422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。